Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran for Hereditary Angioedema
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
